Abstract
Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuses on its origin, molecular and clinical characteristics, and treatment.
Publication types
- Research Support, Non-U.S. Gov't
- Review
MeSH terms
- Antineoplastic Agents / therapeutic use*
- Breast Neoplasms* / drug therapy
- Breast Neoplasms* / immunology
- Breast Neoplasms* / mortality
- Breast Neoplasms* / pathology
- Female
- Genes, BRCA1
- Humans
- Mutation
- Prognosis
- Receptor, ErbB-2
- Receptors, Estrogen
- Receptors, Progesterone
- Survival Rate
Substances
- Antineoplastic Agents
- Receptors, Estrogen
- Receptors, Progesterone
- Receptor, ErbB-2